Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells

作者：Gatti Giuliana; Lucini Valeria; Dugnani Silvana; Calastretti Angela; Spadoni Gilberto; Bedini Annalida; Rivara Silvia; Mor Marco; Canti Gianfranco; Scaglione Francesco; Bevilacqua Annamaria^*

来源：Oncotarget, 2017, 8(40): 68338-68353.

DOI：10.18632/oncotarget.20124

• melatonin analogues
• melatonin receptors
• anti-cancer drugs
• melanoma
• breast cancer

Melatonin plays different physiological functions ranging from the regulation of circadian rhythms to tumor inhibition, owing to its antioxidant, immunomodulatory and anti-aging properties. Due to its pleiotropic functions, melatonin has been shown to elicit cytoprotective processes in normal cells and trigger pro-apoptotic signals in cancer cells. The therapeutic potential of melatonin analogues prompted us to investigate the in vitro and in vivo antitumor activity of new melatonin derivatives and explore the underlying molecular mechanisms. The experiments revealed that the new melatonin analogues inhibited the growth of melanoma and breast cancer cells in a dose-and time-dependent manner. In addition, our results indicated that melatonin derivative UCM 1037 could induce apoptosis in melanoma and breast cancer cells, as well as cell necrosis, in MCF-7. Together, apoptosis and necrosis could be two possible mechanisms to explain the cytotoxic effect of the melatonin analogue against cancer cells. The suppression of tumor growth by the melatonin analogues was further demonstrated in vivo in a xenograft mice model. A decrease in the activation of MAPK pathway was observed in all cancer cells following UCM 1037 treatment. Overall, this study describes a promising antitumor compound showing antiproliferative and cytotoxic activity in melanoma and breast cancer cells.

• 出版日期2017-9-15